Xencor | XNCR - Interest Income


Xencor reported $7.25M in Interest Income for its fiscal quarter ending in June of 2025.



Financials
Stock Price USD
Assets USD 879.42M
Cash and Equivalent USD 44.44M
Cost of Sales USD 61.66M
Current Assets USD 513.15M
Current Liabilities USD 96.08M
Debt USD 67.93M
EBIT USD -22.83M
EBITDA USD -30.52M
Employees 250
EPS Earnings Per Share USD -0.41
Equity Capital and Reserves USD 620.35M
Gross Profit on Sales USD 43.61M
Interest Expense on Debt USD 8.24M
Interest Income USD 7.25M
Loan Capital USD 94.74M
Market Capitalization USD 522.6M
Net Income USD -30.83M
Operating Expenses USD 76.78M
Operating Profit USD -33.17M
Ordinary Share Capital USD 71.3M
PE Price to Earnings USD 29.92
Pre-Tax Profit USD -31.08M
Sales Revenues USD 43.61M
Selling and Administration Expenses USD 15.12M
Stock USD 0
Trade Creditors USD 18.53M
Trade Debtors USD 47.55M

Interest Income Change Date
AbbVie USD 73M 19M Mar/2025
Alnylam Pharmaceuticals USD 27.49M 1.19M Jun/2025
Arrowhead Research USD 9.62M 2.01M Mar/2025
AstraZeneca USD 68M 16M Jun/2025
Biogen USD 32.3M 8.4M Jun/2025
Cytokinetics USD 13.7M 1.31M Mar/2025
GlaxoSmithKline GBP 50M 4M Jun/2025
J&J USD 332M 51M Mar/2025
MacroGenics USD 1.41M 1.41M Jun/2025
Merck USD 109M 37M Mar/2025
Pfizer USD 156M 13M Jun/2025
Regeneron Pharmaceuticals USD 174.8M 1.3M Jun/2025
Roche Holding CHF 2M 12M Dec/2020
Xencor USD 7.25M 290K Jun/2025